Angiogenesis gene therapy to rescue ischaemic tissues: achievements and future directions
- 1 August 2001
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 133 (7) , 951-958
- https://doi.org/10.1038/sj.bjp.0704155
Abstract
Ischaemic diseases are characterized by an impaired supply of blood resulting from narrowed or blocked arteries that starve tissues of needed nutrients and oxygen. Coronary-atherosclerosis induced myocardial infarction is one of the leading causes of mortality in developed countries. Ischaemic disease also affects the lower extremities. Considerable advances in both surgical bypassing and percutaneous revascularization techniques have been reached. However, many patients cannot benefit from these therapies because of the extension of arterial occlusion and/or microcirculation impairment. Consequently, the need for alternative therapeutic strategies is compelling. An innovative approach consists of stimulating collateral vessel growth, a natural host defence response that intervenes upon occurrence of critical reduction in tissue perfusion (Isner & Asahara, 1999). This review will debate the relevance of therapeutic angiogenesis for promotion of tissue repair. The following issues will receive attention: (a) vascular growth patterns, (b) delivery systems for angiogenesis gene transfer, (c) achievements of therapeutic angiogenesis in myocardial and peripheral ischaemia, and (d) future directions to improve effectiveness and safety of vascular gene therapy.Keywords
This publication has 72 references indexed in Scilit:
- Upregulation of bradykinin B1-receptor expression after myocardial infarctionBritish Journal of Pharmacology, 2000
- The Use of Adeno-Associated Virus to Circumvent the Maturation-Dependent Viral Transduction of Muscle FibersHuman Gene Therapy, 2000
- Adenovirus-Mediated Acidic Fibroblast Growth Factor Gene Transfer Induces Angiogenesis in the Nonischemic Rabbit HeartMicrovascular Research, 1999
- Progress in Adeno-Associated Virus Type 2 Vector Production: Promises and Prospects for Clinical UseHuman Gene Therapy, 1999
- Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularizationJournal of Clinical Investigation, 1999
- Rescue of Diabetes-Related Impairment of Angiogenesis by Intramuscular Gene Therapy with Adeno-VEGFThe American Journal of Pathology, 1999
- Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector Containing theE. coliCytosine Deaminase Gene to Metastatic Colon Carcinoma of the Liver in Association with the Oral Administration of the Pro-Drug 5-Fluorocytosine. The New York Hospital-Cornell Medical Center, New York, NYHuman Gene Therapy, 1997
- Blockade of Bradykinin B 2 Receptors Prevents the Increase in Capillary Density Induced by Chronic Angiotensin-Converting Enzyme Inhibitor Treatment in Stroke-Prone Spontaneously Hypertensive RatsHypertension, 1997
- Systemic and Portal Vein Delivery of Human Kallikrein Gene Reduces Blood Pressure in Hypertensive RatsHuman Gene Therapy, 1996
- VasculogenesisAnnual Review of Cell and Developmental Biology, 1995